Disclosed is (a) an antibody or an antigen-binding portion thereof that specifically binds to and inhibits Programmed Death-1 (PD-1) and/or an antibody or an antigen–binding protein portion thereof that specifically binds to and inhibits Programmed Death-L1 (PD-L1)； (b) an antibody or an antigen-binding portion thereof that specifically binds to and inhibits Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4)； and (c) Interleukin-2 (IL-2) for use in the treatment of a cancer patient, wherein the body core temperature of said patient is kept at a temperature of 39.0°C to 40.5°C, preferably of 39.5°C to 40.5°C for at least 5 h per day for at least 4, preferably at least 5, consecutive days.
